Systemic administration of ß2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.

Keyphrases

• Salmeterol 100%
• Systemic Administration 100%
• Formoterol 100%
• Adrenoceptor Agonist 100%
• Skeletal muscle Hypertrophy 100%
• Skeletal muscle 27%
• Adrenoceptors 27%
• EDL muscle 27%
• Muscle Hypertrophy 18%
• Soleus muscle 18%
• Hypertrophy 18%
• Cardiac muscle 18%
• Intrinsic Activity 18%
• Muscle Wasting 18%
• Young Males 9%
• Soleus 9%
• Adverse Effects 9%
• Asthma 9%
• Muscle Mass 9%
• Dose-response Curve 9%
• Therapeutic Use 9%
• Duration of Action 9%
• Extended Duration 9%
• Cardiac Hypertrophy 9%
• Potential Therapy 9%
• F344 Rats 9%
• Increased Safety 9%
• Pharmacological Profile 9%
• Dose-ranging 9%
• Potential Therapeutics 9%
• Muscle Weakness 9%
• ED50 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Adrenergic Receptor Stimulating Agent 100%
• Systemic Administration 100%
• Formoterol 100%
• Salmeterol 100%
• Muscle Growth 100%
• Adrenergic Receptor 27%
• Heart Ventricle Hypertrophy 18%
• Muscle Atrophy 18%
• Intrinsic Activity 18%
• Fischer 344 Rat 9%
• Therapeutic Use 9%
• Adverse Event 9%
• Asthma 9%
• Muscle Weakness 9%